Shell-and-core dosage form approaching zero-order drug release
View Patent ↗Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also promotes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to a size that is retained in the stomach during the postprandial or fed mode.
1. A controlled-release oral drug dosage form for releasing a drug into at least a portion of a region defined by the stomach and the upper gastrointestinal tract, said dosage form comprising:
(a) a core comprising a first solid polymeric matrix with said drug dispersed therein, and
(b) a shell encasing said core, said shell comprising a second solid polymeric matrix that swells upon imbibition of water to a size large enough to promote retention in the stomach while the stomach is in a fed mode, and said shell having a drug:polymer weight ratio that is less than that of said core, said shell having a thickness that is at least about 0.5% of the longest linear dimension of said dosage form, said second polymeric matrix being of a material and thickness relative to said core such that when said dosage form is immersed in gastric fluid, said drug is released from said dosage form into said gastric fluid at a controlled rate by diffusion of said drug through said shell during substantially the entire period of drug release such that at least about 40% of said drug remains unreleased one hour after such immersion has begun and substantially all of said drug is released within about twenty-four hours after such immersion has begun, said shell remaining intact during substantially the entire period of drug release, wherein said first solid polymeric matrix and said second polymeric matrix comprise a polymer independently selected from the group consisting of a poly(ethylene oxide), a cross-linked polyacrylic acid, and a hydroxyalkyl-substituted cellulose.
2. A controlled-release oral drug form in accordance with claim 1 in which said drug is dispersed in the shell.
3. A controlled-release oral drug dosage form in accordance with claim 2 in which said core has an outer surface and said shell has an inner surface in full contact with said outer surface of said core.
4. A controlled-release oral drug dosage form in accordance with claim 2 in which said shell thickness is from about 1% to about 60% of the longest linear dimension of said dosage form.
5. A controlled-release oral drug dosage form in accordance with claim 2 in which said shell thickness is from about 1.5% to about 45% of the longest linear dimension of said dosage form.
6. A controlled-release oral drug dosage form in accordance with claim 2 in which said shell thickness is from about 2% to about 30% of the longest linear dimension of said dosage form.
7. A controlled release oral drug dosage form in accordance with claim 2 in which the drug:polymer weight ratio of said shell is equal to or less than about 0.25 times the drug:polymer weight ratio of said core.
8. A controlled release oral drug dosage form in accordance with claim 2 in which the drug:polymer weight ratio of said shell is equal to or less than about 0.05 times the drug:polymer weight ratio of said core.
9. A controlled-release oral drug dosage form in accordance with claim 1 in which said oral drug dosage form is a tablet having a total weight of from about 50 mg to about 5000 mg.
10. A controlled-release oral drug dosage form in accordance with claim 1 in which said oral drug dosage form is a tablet having a total weight of from about 100 mg to about 3000 mg.
11. A controlled-release oral drug dosage form in accordance with claim 2 in which said oral drug dosage form is a tablet having a total weight of from about 500 mg to about 2000 mg.
12. A controlled-release oral drug dosage form in accordance with claim 2 in which said first and second polymeric matrices are formed of polymers independently selected from the group consisting of poly(ethylene oxide), hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropylmethyl cellulose.
13. A controlled-release oral drug dosage form in accordance with claim 2 in which said first and second polymeric matrices are formed of polymers independently selected from the group consisting of poly(ethylene oxide), hydroxypropylmethyl cellulose, and hydroxyethyl cellulose.
14. A controlled-release oral drug dosage form in accordance with claim 2 in which said first and second polymeric matrices are both poly(ethylene oxide).
15. A controlled-release oral drug dosage form in accordance with claim 2 in which said poly(ethylene oxide) has a molecular weight of at least about 2,000,000.
16. A controlled-release oral drug dosage form in accordance with claim 2 in which said poly(ethylene oxide) has a molecular weight of from about 2,000,000 to about 10,000,000.
17. A controlled-release oral drug dosage form in accordance with claim 2 in which said poly(ethylene oxide) of said first polymeric matrix has a higher molecular weight than said poly(ethylene oxide) of said second polymeric matrix.
18. A controlled-release oral drug dosage form in accordance with claim 2 in which said poly(ethylene oxide) of said first polymeric matrix has a lower molecular weight than said poly(ethylene oxide) of said second polymeric matrix.
19. A controlled-release oral drug dosage form in accordance with claim 2 in which the molecular weight ratio of said poly(ethylene oxide) of said first polymeric matrix to said poly(ethylene oxide) of said second polymeric matrix is from about 1.15:1 to about 2.5:1.
20. A controlled-release oral drug dosage form in accordance with claim 2 in which the amount of said drug in said core is from about 1% to about 98% by weight.
21. A controlled-release oral drug dosage form in accordance with claim 2 in which the amount of said drug in said core is from about 5% to about 95% by weight.
22. A controlled-release oral drug dosage form in accordance with claim 2 in which the amount of said drug in said core is from about 50% to about 93% by weight.
23. A controlled-release oral drug dosage form in accordance with claim 2 in which said second polymeric matrix is of a material and volume relative to said core that at least about 40% of said drug remains unreleased two hours after such immersion has begun.
24. A controlled-release oral drug dosage form in accordance with claim 2 in which said second polymeric matrix is of a material and volume relative to said core that at least about 60% of said drug remains unreleased two hours after such immersion has begun.
25. A controlled-release oral drug dosage form in accordance with claim 2 in which said second polymeric matrix is of a material and volume relative to said core that at least about 70% of said drug remains unreleased two hours after such immersion has begun.
26. A controlled-release oral drug dosage form in accordance with claim 2 in which said drug has a solubility in water of greater than one part by weight of said drug in 25 parts by weight of water.
27. A controlled-release oral drug dosage form in accordance with claim 2 in which said drug has a solubility in water of greater than one part by weight of said drug in ten parts by weight of water.
28. A controlled-release oral drug dosage form in accordance with claim 2 in which said drug is a member selected from the group consisting of metformin hydrochloride, vancomycin hydrochloride, captopril, lisinopril, erythromycin lactobionate, acyclovir, ranitidine hydrochloride, baclofen, sertraline hydrochloride, levodopa, tramadol, and ticlopidine hydrochloride.
29. A controlled-release oral drug dosage form in accordance with claim 1 in which said drug is a member selected from the group consisting of amoxicillin, cefuroxime axetil, cefaclor, clindamycin, clarithromycin, azithromycin, ceftazidine, and ciprofloxacin.
30. A controlled-release oral drug dosage form in accordance with claim 1 in which said drug is a member selected from the group consisting of cyclosporine, digoxin, doxifluridine, and paclitaxel.
31. A controlled-release oral drug dosage form in accordance with claim 1 in which said drug is a member selected from the group consisting of esters of ampicillin, iron salts, digoxin, and ketoconazole.
32. A controlled-release oral drug dosage form in accordance with claim 1 in which said drug is nelfinar mesylate.
33. A controlled-release oral drug dosage form in accordance with claim 1 in which said shell contains substantially none of said drug.
34. A controlled-release oral drug dosage form in accordance with claim 33 in which said core has an outer surface and said shell has an inner surface in full contact with said outer surface of said core.
35. A controlled-release oral drug dosage form in accordance with claim 33 in which said shell thickness is from about 1% to about 60% of the longest linear dimension of said dosage form.
36. A controlled-release oral drug dosage form in accordance with claim 33 in which said shell thickness is from about 1.5% to about 45% of the longest linear dimension of said dosage form.
37. A controlled-release oral drug dosage form in accordance with claim 33 in which said shell thickness is from about 2% to about 30% of the longest linear dimension of said dosage form.
38. A controlled-release oral drug dosage form in accordance with claim 33 in which said oral drug dosage form is a tablet having a total weight of from about 500 mg to about 2000 mg.
39. A controlled-release oral drug dosage form in accordance with claim 33 in which said first and second polymeric matrices are formed of polymers independently selected from the group consisting of poly(ethylene oxide), hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropylmethyl cellulose.
40. A controlled-release oral drug dosage form in accordance with claim 33 in which said first and second polymeric matrices are formed of polymers independently selected from the group consisting of poly(ethylene oxide), hydroxypropylmethyl cellulose, and hydroxyethyl cellulose.
41. A controlled-release oral drug dosage form in accordance with claim 33 in which said first and second polymeric matrices are both poly(ethylene oxide).
42. A controlled-release oral drug dosage form in accordance with claim 33 in which said poly(ethylene oxide) has a molecular weight of at least about 2,000,000.
43. A controlled-release oral drug dosage form in accordance with claim 33 in which said poly(ethylene oxide) has a molecular weight of from about 2,000,000 to about 10,000,000.
44. A controlled-release oral drug dosage form in accordance with claim 33 in which said poly(ethylene oxide) of said first polymeric matrix has a higher molecular weight than said poly(ethylene oxide) of said second polymeric matrix.
45. A controlled-release oral drug dosage form in accordance with claim 33 in which said poly(ethylene oxide) of said first polymeric matrix has a lower molecular weight than said poly(ethylene oxide) of said second polymeric matrix.
46. A controlled-release oral drug dosage form in accordance with claim 33 in which the molecular weight ratio of said poly(ethylene oxide) of said first polymeric matrix to said poly(ethylene oxide) of said second polymeric matrix is from about 1.15:1 to about 2.5:1.
47. A controlled-release oral drug dosage form in accordance with claim 33 in which said second polymeric matrix is of a material and volume relative to said core that at least about 40% of said drug remains unreleased two hours after such immersion has begun.
48. A controlled-release oral drug dosage form in accordance with claim 33 in which said second polymeric matrix is of a material and volume relative to said core that at least about 60% of said drug remains unreleased two hours after such immersion has begun.
49. A controlled-release oral drug dosage form in accordance with claim 33 in which said second polymeric matrix is of a material and volume relative to said core that at least about 70% of said drug remains unreleased two hours after such immersion has begun.
50. A controlled-release oral drug dosage form in accordance with claim 33 in which said drug has a solubility in water of greater than one part by weight of said drug in 25 parts by weight of water.
51. A controlled-release oral drug dosage form in accordance with claim 33 in which said drug has a solubility in water of greater than one part by weight of said drug in ten parts by weight of water.
52. A controlled-release oral drug dosage form in accordance with claim 33 in which said drug is a member selected from the group consisting of metformin hydrochloride, vancomycin hydrochloride, captopril, lisinopril, erythromycin lactobionate, acyclovir, ranitidine hydrochloride, baclofen, sertraline hydrochloride, levodopa, tramadol, and ticlopidine hydrochloride.
53. A controlled-release oral drug dosage form in accordance with claim 1 comprising two or more drugs.
54. A controlled-release oral drug dosage form in accordance with claim 53 wherein the two or more drugs are present throughout the dosage form.
55. A controlled-release oral drug dosage form in accordance with claim 53 wherein a first drug is dispersed in the core and a second drug is dispersed in the shell.